Lee, Hee Yang Yoon, Soljee Lee, Jeong Hwa 박근완 Jung, Youngeun Cho, Illhwan Lee, Donghee Shin, Jisu Kim, Kyeonghwan Kim, Sunmi Kim, Jimin Kim, Koeun Han, Seung Hoon Kim, Seong Muk Kim, Hye Ju Kim, Hye Yun Kim, Ikyon Kim, Young Soo 2024-01-12T02:35:00Z 2024-01-12T02:35:00Z 2022-12-09 2022-11 1758-9193 https://pubs.kist.re.kr/handle/201004/75921 Aggregated amyloid-β (Aβ) is considered a pathogenic initiator of Alzheimer’s disease (AD), in strong association with tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and cognitive decline. As the removal of amyloid burden from AD patient brains by antibodies has shown therapeutic potential, the development of small molecule drugs inducing chemical dissociation and clearance of Aβ is compelling as a therapeutic strategy. In this study, we synthesized and screened aryloxypropanolamine derivatives and identified 1-(3-(2,4-di-tert-pentylphenoxy)-2-hydroxypropyl)pyrrolidin-1-ium chloride, YIAD002, as a strong dissociator of Aβ aggregates. English BioMed Central Aryloxypropanolamine targets amyloid aggregates and reverses Alzheimer-like phenotypes in Alzheimer mouse models Article 10.1186/s13195-022-01112-6 1 Alzheimer's Research and Therapy, v.14, no.1 Alzheimer's Research and Therapy 14 1 Y scie scopus 000889549900001 Clinical Neurology Neurosciences Neurosciences & Neurology Article TAU AGGREGATION BETA ASSAY ABNORMALITIES TOXICITY Alzheimer&apos s disease Amyloid-beta Drug discovery Tau Small molecule